168 related articles for article (PubMed ID: 33428904)
1. Myeloid NEMO deficiency promotes tumor immunosuppression partly via MCP1-CCR2 axis.
Yuanyuan L; Yakun L; Zhongyao L; Le Y; Weisong D; Moran G; Hui B; Chunyan L
Exp Cell Res; 2021 Feb; 399(2):112467. PubMed ID: 33428904
[TBL] [Abstract][Full Text] [Related]
2. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
3. Roles of CCR2 and CCR5 for Hepatic Macrophage Polarization in Mice With Liver Parenchymal Cell-Specific NEMO Deletion.
Bartneck M; Koppe C; Fech V; Warzecha KT; Kohlhepp M; Huss S; Weiskirchen R; Trautwein C; Luedde T; Tacke F
Cell Mol Gastroenterol Hepatol; 2021; 11(2):327-347. PubMed ID: 32896623
[TBL] [Abstract][Full Text] [Related]
4. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.
Huang B; Lei Z; Zhao J; Gong W; Liu J; Chen Z; Liu Y; Li D; Yuan Y; Zhang GM; Feng ZH
Cancer Lett; 2007 Jul; 252(1):86-92. PubMed ID: 17257744
[TBL] [Abstract][Full Text] [Related]
5. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2
Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK
Front Immunol; 2022; 13():993444. PubMed ID: 36685592
[TBL] [Abstract][Full Text] [Related]
6. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.
Teng KY; Han J; Zhang X; Hsu SH; He S; Wani NA; Barajas JM; Snyder LA; Frankel WL; Caligiuri MA; Jacob ST; Yu J; Ghoshal K
Mol Cancer Ther; 2017 Feb; 16(2):312-322. PubMed ID: 27980102
[TBL] [Abstract][Full Text] [Related]
7. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
Lesokhin AM; Hohl TM; Kitano S; Cortez C; Hirschhorn-Cymerman D; Avogadri F; Rizzuto GA; Lazarus JJ; Pamer EG; Houghton AN; Merghoub T; Wolchok JD
Cancer Res; 2012 Feb; 72(4):876-86. PubMed ID: 22174368
[TBL] [Abstract][Full Text] [Related]
8. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
Fei L; Ren X; Yu H; Zhan Y
Front Immunol; 2021; 12():771210. PubMed ID: 34804061
[TBL] [Abstract][Full Text] [Related]
9. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
10. Monocytic myeloid-derived suppressor cells home to tumor-draining lymph nodes via CCR2 and locally modulate the immune response.
Lahmar Q; Schouppe E; Morias Y; Van Overmeire E; De Baetselier P; Movahedi K; Laoui D; Sarukhan A; Van Ginderachter JA
Cell Immunol; 2021 Apr; 362():104296. PubMed ID: 33556903
[TBL] [Abstract][Full Text] [Related]
11. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract][Full Text] [Related]
12. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
[TBL] [Abstract][Full Text] [Related]
13. Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1.
Boelte KC; Gordy LE; Joyce S; Thompson MA; Yang L; Lin PC
PLoS One; 2011 Apr; 6(4):e18534. PubMed ID: 21494556
[TBL] [Abstract][Full Text] [Related]
14. Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer.
Burfeind KG; Zhu X; Norgard MA; Levasseur PR; Huisman C; Buenafe AC; Olson B; Michaelis KA; Torres ER; Jeng S; McWeeney S; Raber J; Marks DL
Elife; 2020 May; 9():. PubMed ID: 32391790
[TBL] [Abstract][Full Text] [Related]
15. Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth.
Achyut BR; Angara K; Jain M; Borin TF; Rashid MH; Iskander ASM; Ara R; Kolhe R; Howard S; Venugopal N; Rodriguez PC; Bradford JW; Arbab AS
Sci Rep; 2017 Oct; 7(1):13754. PubMed ID: 29062041
[TBL] [Abstract][Full Text] [Related]
16. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
Li BH; Garstka MA; Li ZF
Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
[TBL] [Abstract][Full Text] [Related]
17. The CCR2
Bartneck M; Schrammen PL; Möckel D; Govaere O; Liepelt A; Krenkel O; Ergen C; McCain MV; Eulberg D; Luedde T; Trautwein C; Kiessling F; Reeves H; Lammers T; Tacke F
Cell Mol Gastroenterol Hepatol; 2019; 7(2):371-390. PubMed ID: 30704985
[TBL] [Abstract][Full Text] [Related]
18. Myeloid Deletion of Nemo Causes Osteopetrosis in Mice Owing to Upregulation of Transcriptional Repressors.
Swarnkar G; Shim K; Nasir AM; Seehra K; Chen HP; Mbalaviele G; Abu-Amer Y
Sci Rep; 2016 Jul; 6():29896. PubMed ID: 27435916
[TBL] [Abstract][Full Text] [Related]
19. Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion.
Li F; Kitajima S; Kohno S; Yoshida A; Tange S; Sasaki S; Okada N; Nishimoto Y; Muranaka H; Nagatani N; Suzuki M; Masuda S; Thai TC; Nishiuchi T; Tanaka T; Barbie DA; Mukaida N; Takahashi C
Cancer Res; 2019 Aug; 79(15):3903-3915. PubMed ID: 31189648
[TBL] [Abstract][Full Text] [Related]
20. The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.
Hartwig T; Montinaro A; von Karstedt S; Sevko A; Surinova S; Chakravarthy A; Taraborrelli L; Draber P; Lafont E; Arce Vargas F; El-Bahrawy MA; Quezada SA; Walczak H
Mol Cell; 2017 Feb; 65(4):730-742.e5. PubMed ID: 28212753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
